Glial reactions in Parkinson's disease

McGeer, Patrick L., McGeer, Edith G.·2008·Movement Disorders
DOI 10.1002/mds.21751

Cited by (700)

Items 601–700 of 700

  1. Neuropathology of Movement Disorders
    K. A. Jellinger · 2011 · Elsevier eBooks
  2. Light Therapy in Parkinson’s Disease
    Michael Besser AM · 2022 · Biomedical Journal of Scientific & Technical Research
  3. Small Extracellular Vesicles Secreted by Region-specific Astrocytes Ameliorate the Mitochondrial Function in a Cellular Model of Parkinson’s Disease
    Loredana Leggio, Francesca L’Episcopo, Andrea Magrì, María José Ulloa-Navas, Greta Paternò, Silvia Vivarelli, Carlos A. P. Bastos, Cataldo Tirolo, Nunzio Testa, Salvatore Caniglia et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  4. Anti-inflammatory Role of GM1 and Other Gangliosides on Microglia
    Simonetta Sipione, Danny Galleguillos, Qian Wang, Noam Steinberg, Asifa K. Zaidi, Gaurav Shrivastava, Kamaldeep Dhami, Gour Chand Daskhan, Edward N. Schmidt, Zoë Dworsky-Fried et al. · 2021 · Research Square
  5. Cannabis Compounds: Potential Therapy for Neurological Disease
    Mariana Babayeva, Zvi G. Loewy · 2024 · IntechOpen eBooks
  6. Liver X receptor α contribution to neuroinflammation and glial cells activation induced by MPTP: Implications for Parkinson’s disease
    Zhihao Mao, Yuning Zhang, Yirong Liang, Chenglai Xia, Lan Tang · 2024 · Neuroscience
  7. MPP+ disorders Irg1-Itaconate axis to promote M1 polarization of microglia by activating succinate dehydrogenase
    Lin‐Yu Wang, Yi-Yun Tang, Wei Zou, Ping Zhang, Xiao‐Qing Tang, Ping Zhang · 2025 · Molecular Biology Reports
  8. Impact of aging on the central and enteric nervous system in a Parkinson’s disease mouse model
    Solène Pradeloux, Morgane M. André, Maélie Fréchette, Mathilde Drolet, Catherine Fontaine-lavallée, Mélissa Côté, Katherine Coulombe, Marie Rieux, Frédéric Calon, Denis Soulet · 2025 · Frontiers in Aging Neuroscience
  9. Potential role of splice junctions of α-synuclein isoforms in the activation of T-cells: Implications for Parkinson's disease
    Shweta Kaul, Aravind Vulli, Shasi V. Kalivendi · 2026 · Cellular Signalling
  10. Blood-based biomarkers of ferroptosis in Parkinson's disease
    Vincent Huin, Émeline Cailliau, Clément Poupelin, Guillaume Garçon, Mary Dutheil, Ophélie Simonin, Nicolas Beauval, Julien Labreuche, David L Blum, Caroline Moreau et al. · 2026 · Neurobiology of Disease
  11. Activated microglial phenotypes in the hippocampal CA2 subfield are implicated in Lewy body disease progression
    Esteban Luna, Katheryn A Q Cousins, Sheina Emrani, Sharon X. Xie, Winifred Trotman, Noah Capp, Philip Sabatini, Parham Pouladvand, EunRan R. Suh, Vivianna M. Van Deerlin et al. · 2026 · Acta Neuropathologica
  12. STRESS AND INFLAMMATION: A DETRIMENTAL COMBINATION IN THE DEVELOPMENT OF NEURODEGENERATIVE DISEASE.
    Rocío M. de Pablos, Ana M. Espinosa‐Oliva, Manuel Sarmiento Soto, Jose Luis Venero · 2014 · Inflammation and Cell Signaling
  13. Pluripotent Stem Cell-Derived Dopaminergic Neurons As Models of Neurodegeneration
    Bradley Watmuff, Brigham J. Hartley, Cameron P. J. Hunt, Colin William Pouton, John M. Haynes · 2013 · Future Neurology
  14. The role of microglia–lymphocyte interaction in PD neuropathology
    Anna Rosa Carta · 2012 · Basal Ganglia
  15. Chronic Peripheral Treatment with Mediated Loss following - Oxidative Stress Dopaminergic Neurons Contributes to Their 1 Expression in α Cutting Edge: IL-13R
    Pamela A Maher, Shuei Sugama, Berenice Del Carmen Sánchez-González, Indrek Saar, Kwang‐Soo Kim, Daniel K. Nomura, Manuel Sánchez-Alavez, E.S. Morrison, Maria Cecília Garibaldi Marcondes · 2012
  16. Minocycline exerts a neuroprotective action against 6-OHDA-induced neurotoxicity: in vivo and in vitro studies
    Pollyanna Landim Falcão Tavares Ferreira, Glauce Socorro de Barros Viana · 2015 · Neurology and Neuroscience
  17. 6Chapter Micronutrients for the Prevention of Diabetes and Improvement of the Standard Therapy
    Kedar N. Prasad · 2010 · CRC Press eBooks
  18. Is Chronic Systemic Inflammation a Determinant Factor in Developing Parkinson’s Disease?
    Perla Ugalde‐Muñiz, Jesús Pérez‐Hernández, Anahí Chavarría · 2016 · InTech eBooks
  19. MPTP: Advances from an Evergreen Neurotoxin
    Anna Rosa Carta, Augusta Pisanu, Carlos Barcia, María Trinidad Herrero · 2014 · Springer eBooks
  20. The experimental evidence for photobiomodulation-induced cellular and behavioral changes in animal models of Parkinson’s disease: a template for translation to patients
    Nabil El Massri, John Mitrofanis · 2019 · Elsevier eBooks
  21. Autoimmunity
    Marco Cosentino, Nataša Z. Kuštrimović, Franca Marino · 2016 · Springer eBooks
  22. Phospholipase C and glutamate excitotoxicity as etiological mechanism in neurological disorders
    Afaf K El-Ansary, Abir G Ben Bacha, Sohair Aly Hassan · 2023 · Elsevier eBooks
  23. Neuropathology of Neurological Disorders
    Mashoque Ahmad Rather, Andleeb Khan, Hayate Javed, Sadaf Jahan, Rizwana Tabassum, Rubia Begum · 2024 · Springer eBooks
  24. Recent advances in neurodegenerative disease research
    Ekta Singh, Rahul Dilawari · 2024 · Elsevier eBooks
  25. Neuroinflammation, glymphatic system, and Parkinson's disease
    Sohaila Mohammed Salah Saleh, Nada Nasser, Engy K. Tharwat, Tasneem Elbehiry, Hagar Ismail Helmy · 2024 · Elsevier eBooks
  26. In Vivo Systems: Animal Models of Neurodegeneration*
    X. Zhang, Merle G. Paule · 2010 · Elsevier eBooks
  27. Micronutrients for the Prevention and Improvement of the Standard Therapy for Parkinson’s Disease
    Kedar Nath Prasad · 2019 · CRC Press eBooks
  28. Determinants of Selective Vulnerability of Dopamine Neurons in Parkinson's Disease
    Enrico Zampese, Daniel J. Galtieri, Paul T. Schumacker, Dalton James Surmeier · 2016 · Handbook of behavioral neuroscience
  29. Stem Cell-Based Therapies for Parkinson’s Disease
    Charlotte Palmer, Isabel Liste · 2017 · Stem cells in clinical applications
  30. Astrocytes and microglia in Parkinson's disease and animal models
    K. Kuter · 2020 · Elsevier eBooks
  31. In Vivo Systems: Animal Models of Neurodegeneration
    Xilan Zhang, M.G. Paule · 2014 · Elsevier eBooks
  32. Parkinson's disease and a dopamine-derived neurotoxin, 3,4-Dihydroxyphenylacetaldehyde
    Laurie L. Eckert · 2012
  33. Modulation of the ROCK pathway in models of Parkinson´s disease
    Kim Ann Saal · 2015
  34. Erythropoietin as a Modulator of Pathology in a Toxicant Mouse Model of Parkinson’s Disease
    Ashley Thompson · 2019
  35. Enfermedad de Parkinson: Modificaciones oxidativas y su rol en la toxicidad de α-sinucleína
    Ezequiel Giménez · 2022
  36. Microglial reactivity in the hippocampal CA2 is associated with advanced neuronal α-synucleinopathy
    Esteban Luna, Katheryn A Q Cousins, Sheina Emrani, Sharon X. Xie, Winifred Trotman, Daniel A. Weintraub, Alice S. Chen‐Plotkin, Edward B. Lee, David John Irwin · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  37. Place de l'activation microgliale associée à la dégénérescence des neurones dopaminergiques provoquée par la 6-OHDA chez le rat : implication dans la compréhension de la pathogénie de la maladie de Parkinson
    Vincent Henry · 2008 · OpenGrey (Institut de l'Information Scientifique et Technique)
  38. Dopaminergic Dysfunction in Experimental Hepatic Encephalopathy
    Isabel Suárez, Guillermo Bodega, Benjamı́n Fernández · 2012 · InTech eBooks
  39. Análise da mobilidade mitocondrial em células vivas do hipocampo, substância negra e locus coeruleus anterior à agregação proteica envolvida em neurodegeneração
    Stephanie Martins · 2013
  40. Neuropathology of Dementia in Parkinson's Disease
    Dennis W. Dickson, Carolyn Orr · 2011 · Parkinson s Disease
  41. Transcription factor control in neuronal maintenance and survival
    Banafsheh Kadkhodaei · 2010 · Figshare
  42. Glial Cell Activation in PD
    Koichi Wakabayashi · 2010 · Elsevier eBooks
  43. Pogostemon Cabin prevents the MPTP-induced loss of dopaminergic neurons by inhibiting CD4+ T cell infiltration in the brain
    Minsook Ye, Hwansoo Joo, Kye Seok Lee, Won Seob Kim, Hyunsu Bae · 2014 · Oriental Pharmacy and Experimental Medicine
  44. Immunohistochemical and Morphological Changes in Neurons and Neuroglia in the Cerebral Nigrostriatal Structures under Conditions of Experimental Nigral Neurodegeneration
    Р. М. Худоерков, Д. Н. Воронков, N. G. Yamshchikova · 2012 · Bulletin of Experimental Biology and Medicine
  45. A signaling axis, Parkinson's disease and obesity
    Hong-Bin Qu · 2009 · Bioscience hypotheses
  46. Corrigendum to ‘Immunoprotection against toxic biomarkers is retained during Parkinson's disease progression’ [Journal of Neuroimmunology, 233 (2011) 221–227]
    Грудень Марина Алексеевна, Robert D. E. Sewell, Kiran Yanamandra, T.V. Davidova, Valery G. Kucheryanu, Evgeny V. Bocharov, Olga A. Bocharova, Vsevolod V. Poleschuk, Vladimir V. Sherstnev, Ludmilla A. Morozova‐Roche · 2014 · Journal of Neuroimmunology
  47. Vasoactive Neuropeptides in Autoimmune Diseases
    Ekua W. Brenu, Lotti Tajouri, Donald Staines, Sonya M. Marshall-Gradisnik · 2011 · InTech eBooks
  48. Discovery of a nitric oxide synthase-dependent response and a functional analysis of genes regulating the response in a Drosophila model of Parkinson's disease
    Arati A. Inamdar · 2009
  49. Treating neuroinflammation: Exploring its potential in Parkinson's disease
    Musharrat Jabeen Ahmed-Landeryou · 2009 · British Journal of Neuroscience Nursing
  50. Evidence of oligodendrogliosis in MPTP-induced Parkinsonism 1
    Valentina Annese, Carlos Barcia, Francisco Ros‐Bernal, Abraham Bernárdez-Gómez, Carmen María Brugarolas Ros, Vicente de Pablos, Maria Egle De Stefano, María Trinidad Herrero, Charles R. Darwin · 2012
  51. Die Rolle von Neuromelanin in der Pathogenese desidiopathischen Parkinson Syndroms
    Sebastian Geick · 2011 · Multimedialen Archiv und Publikationsserver der Christian-Albrechts-Universität zu Kiel (Christian-Albrechts-Universität zu Kiel)
  52. Mechanism of Manganese-Induced Impairment of Astrocytic Glutamate Transporters
    Pratap Karki, Keisha Smith, Michael Aschner, Eun-Sook Lee · 2014 · Royal Society of Chemistry eBooks
  53. Influence of electromagnetic field (0,5mT, 50 Hz) on motor behaviour, oxidative stress parameters and morphological characteristics of brain after global cerebral ischemia in mongolian gerbils
    Snezana Raus · 2012
  54. ANIMAL MODEL AND MOLECULAR INTERACTIONS OF CLN5
    Academic Dissert A Tion · 2009
  55. Simultaneous Activation of Nrf2 and Elevation of Dietary and Endogenous Antioxidants for Prevention and Improved Management of Parkinson’s Disease
    Kedar Nath Prasad · 2016 · Oxidative stress in applied basic research and clinical practice
  56. NSAID Use and the Risk of Parkinson's Disease Review and Meta-Analysis of Observational Studies
    Ali Samii, Mahyar Etminan, Matthew O. Wiens, Siavash Jafari · 2009
  57. GDNF and Neurturin isoforms in an experimental model of Parkinson's disease
    Anna‐Maija Penttinen · 2017 · Työväentutkimus Vuosikirja
  58. Changes in Vascular and Immune Cell Content of an LPS Treated Rat Olfactory Bulb PD Model, Measured by Fluorescence Deconvolution Microscopy
    Roger J. Bick, Brian J. Poindexter, Marie Françoise Doursout · 2017 · Journal of Cytokine Biology
  59. Efeito neuroprotetor do antagonismo do receptor P2X7 no Parkinsonismo experimental induzido por 6-OHDA
    Marta Regina Santos do Carmo · 2015 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  60. Avaliação do comprometimento hipotalâmico na secreção de vasopressina durante a sepse
    Luís Henrique Angenendt da Costa · 2017 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  61. Alterações na glia observadas em regiões encefálicas envolvidas no controle respiratório em um modelo animal da doença de Parkinson.
    Kárin Santana de Carvalho · 2018
  62. Pathology and Cell-Based Therapy of Parkinson’s Disease
    So Young Kim, Sung Sik Choi, Dong‐Seok Lee, Seung‐Hoon Lee, Sang Hoon Cha, Hong Jun Lee · 2018 · Springer eBooks
  63. Molecular origins of tissue vulnerability to aberrant aggregation in protein misfolding diseases
    Rosie Freer · 2018 · Apollo (University of Cambridge)
  64. Inflammation and Parkinson's disease : the effect of Poly(I:C) in a toxin-based model of Parkinson's disease
    Jessica Bobyn · 2011
  65. Therapeutic potential of inhibition of the neuroinflammation induced cathepsin X: in vivo evidence
    Anja Hafner Pišlar, Larisa Tratnjek, Gordana Glavan, Nace Zidar, Marko Živin, Janko Kos · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  66. Adult Neurogenesis in Health and Disease
    Arie Sitthichai Mobley · 2019 · Elsevier eBooks
  67. Cerebral administration of alpha-synuclein monomers modulates inflammatory reaction in nigro-striatal system
    Anna Sznejder-Pachołek, Ilona Joniec‐Maciejak, Adriana Wawer, Agnieszka Ciesielska, Dagmara Maria Mirowska-Guzel · 2019 · Journal of Pre-Clinical and Clinical Research
  68. IMAGE DERIVED INPUT FUNCTION FOR BRAIN [11C]TMSX PET IMAGING
    Imran Waggan · 2019 · UTUPub (University of Turku)
  69. Neurons and Plasticity: What Do Glial Cells Have to Do with This?
    Nicolangelo L. Iannella, Michel Condemine · 2020 · Brain informatics and health
  70. Influência do interferon-γ sobre o parkinsonismo, na discinesia induzida pelo tratamento com L-DOPA e na expressão de fatores neuroinflamatórios
    Daniele Pereira Ferrari · 2020 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  71. 6-OHDA ile Oluşturulan Parkinson Hastalığı Modelinde Astrogliozis ve Glutamat Taşıyıcı Protein GLT1 Ekspresyonu
    Zehra Minbay, Bülent Gören, Özhan Eyigör · 2020 · Uludağ Üniversitesi Tıp Fakültesi Dergisi
  72. NR4A Transcription Factor Family: Key Regulators of Memory Formation
    Dina P. Matheos, Marcelo A. Wood · 2020 · Oxford University Press eBooks
  73. Pharmacological, Biochemical and Molecular Investigations in 6-OHDA Induced Parkinson’s Disease Rats on the Protection Benefits of Mangiferin in Behavioral, Inflammatory and Oxidative Biomarkers
    Prafulla Chandra Tiwari, Mayank Jain, Shipra Kartik, Rajendra Nath, Rishi Pal · 2021 · Preprints.org
  74. Alpha-synuclein spreading mechanisms in Parkinson's disease: The role of membrane receptors
    Inês Caldeira Brás, Tiago F. Outeiro · 2021 · International review of movement disorders
  75. Drosophila melanogaster: An Immaculate Model for Glial Research
    Pragati, Shweta Tandon, Aqsa Aqsa, Prerna Aggarwal, Surajit Sarkar · 2022 · Springer eBooks
  76. Parkinsonism and other extrapyramidal diseases
    Elisaveta Sokolov, Vinod Metta, К. Ray Chaudhuri · 2020
  77. Movement disorders
    Marie Vidailhet · 2008 · Current Opinion in Neurology
  78. Mecanismos de protección frente a rotenona por PDGF-BB en un modelo astrocitario
    Ricardo Julián Cabezas Pérez · 2020
  79. Validität human-transgener Mausmodelle für die Parkinson-Krankheit und die Lewy-Körper-Demenz
    Anna Lisa Pülm · 2022
  80. Caracterização do perfil astrocitário na substância negra de ratos com discinesia induzida por L-DOPA e tratados com doxiciclina
    Adrielle Ingrid de Oliveira Barbosa Santiago · 2022
  81. Efeito do acionamento do receptor β2-adrenergico (β2AR) na interação astrócito-micróglia em modelo inflamatório in vitro.
    Paulo César Ferreira dos Santos · 2022 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
  82. Short-Term Effects of Gamma Stimulation on Neuroinflammation at the Tissue-Electrode Interface in Motor Cortex
    Emily Boltcreed, Alpaslan Ersöz, Martin Han, George C. McConnell · 2023 · Neuromodulation Technology at the Neural Interface
  83. O envolvimento da inflamação mediada pela glia nas alterações respiratórias observadas em um modelo murino da Doença de Parkinson.
    Laís M. Cabral · 2023
  84. The interplay between CB 2 and NMDA receptors in Parkinson’s disease
    Jaume Lillo, Iu Raïch, Joan Biel Rebassa, Toni Capó, Pau Badia, Gemma Navarro, Irene Reyes‐Resina · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  85. Neuroinflammatory and neurodegenerative aspects of Parkinson’s disease
    М. А. Никитина, Elena Yu. Bragina, Maria S. Nazarenko, Svetlana А. Ivanova, Anastasiia S. Boiko, Lyudmila A. Levchuk, Valentina Mikhailovna Alifirova · 2025 · S S Korsakov Journal of Neurology and Psychiatry
  86. Optogenetic stimulation of nigral astrocytes is neuroprotective in a 6-OHDA model of neurodegeneration
    Jessica McNeill, Ivan Trujillo‐Pisanty, Stephanie Simard, Chase Groulx, Chris Rudyk, Shawn P. Hayley, Maryam Faiz, Julianna J. Tomlinson, Michael G. Schlossmacher, Gianfilippo Coppola et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  87. Molecular mechanisms of reactive oxygen species in neurodegenerative diseases (Alzheimer, Parkinson, etc.)
    Sanja V. Gluščević · 2025 · Elsevier eBooks
  88. The compounding roles of gut-immune-brain axis and COVID19 in manifestation of idiopathic Parkinson’s disease
    Ankita Das, Vani Vivek, Palok Aich · 2025 · Discover Immunity.
  89. Etude des interactions entre neurones et astrocytes au sein de la substance noire réticulée
    Élodie Barat · 2012 · theses.fr (ABES)
  90. Animal model and molecular interactions of Cln5
    Carina von Schantz · 2009 · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari)
  91. Stem cell therapeutics in neurological disorders: classification, mechanisms and clinical applications
    Ummah Tasnim Nisat, Mycal Dutta, Md. Habib Ullah, Mayeen Uddin Khandaker · 2025 · Elsevier eBooks
  92. Characterizing the Cellular and Molecular Effects of Neural Androgen Receptor Invalidation in Male Mice
    Nida Karameh · 2018 · theses.fr (ABES)
  93. Étude moléculaire de l'inflammation chronique dans la maladie de Parkinson
    Anne‐Claire Compagnion · 2019 · theses.fr (ABES)
  94. C3 and C5 complement cascade activation in brain injury and disease: Molecular mechanisms, pathological roles, and therapeutic implications
    Geoffrey E. Woodard · 2026 · Neurochemistry International
  95. Glial cells in neurodegenerative diseases: a review
    Alif Hasan Pranto, Shahad Saif Khandker, Md Ekhtiar Uddin, Shamima Aktar, Sumaiya Islam Mumu, Rafiul Islam Khan, Nourin Khan Chowdhury, Jarukun Prekbunjun, Asifuzzaman Zisan, Rahima Begum · 2025 · Neurophysiology
  96. Unlocking new uses: The promise of antidepressants in treating Alzheimer's and Parkinson's through Neuroinflammation modulation
    Fatemeh Abbaszadeh, Nahal Babaeian Amini, Samin Davoody, Mohsen Rezaei, Rasoul Ghasemi, Pegah Javadpour · 2026 · Progress in Neuro-Psychopharmacology and Biological Psychiatry
  97. Theranostic Innovative Strategies for Brain Diseases: New Insights on Neurovascular Unit-Associated Pathological Changes in Neurodegenerative Disorders and Aging
    Giulia Terribile, Matilda Pedrinazzi, Irene Frigerio, Giulio Sancini, Romina Combi · 2026 · International Journal of Molecular Sciences
  98. Neuroprotective effect of curcumin against reserpine-induced oxidative damage in the cerebellum of mice in an acute model of Parkinson's disease: Combined in vivo study, molecular docking and molecular dynamics
    Mjid Oukhrib, Lahcen Tamegart, Lamia Hejji, Hafida El Ghachi, Meriem Khedraoui, Ahmed Draoui, Mohammed Haida, Imad Hammoudan, Samir Chtita, Halima Gamrani et al. · 2026 · Research Square
  99. Cholesterol 24S-hydroxylase: Involvement in brain injury and disease
    Casandra M. Cartagena · 2008 · DigitalGeorgetown (Georgetown University Library)
  100. SurR9-C84A mutant nanocarrier and milk protein therapeutics for neurological disorders
    Bhasker Sriramoju · 2014 · Own your potential (DEAKIN)